Friday, December 11, 2015
Global CRO Albany Molecular Research (AMRI) has introduced its new U.S.-based integrated drug discovery center in Buffalo, N.Y.
WuXi PharmaTech, an open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, and PRA Health Sciences, a global clinical CRO, have announced a restructuring of their relationship for the delivery of clinical trial management services in China, Macau and Hong Kong.
Laboratory Corporation of America Holdings (LabCorp), a Burlington, N.C.-based healthcare diagnostics company, has entered into a definitive agreement to acquire substantially all of the operating assets of Pathology Inc., including patient service centers, used to conduct Pathology’s medical testing and services business.
Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has accelerated its study startup timelines globally and has achieved a reduction of mean startup cycle times by up to 25%.
ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has announced the acquisition of PMG Research, an integrated network of clinical research sites operating from 12 metropolitan areas throughout the U.S. The acquisition will enhance ICON’s ability to access and engage with investigator sites and patients, helping customers to reduce the overall time and cost associated with drug development.
Rockville, Md.-based Optimal Research, a clinical research site solution provider, has expanded its network with the addition of a 40-bed, phase I inpatient facility in Austin, Texas.
Turnover in the U.S. for clinical monitoring jobs (the function that monitors participants’ health during a clinical trial) at CROs jumped up to 25.4% from the previous year’s reported low of 16.4%, according to the 17th annual CRO Industry Global Compensation and Turnover Survey, conducted by HR+Survey Solutions, a specialty compensation consulting and research firm. While that number is below the four-year high of 29.4%, it is significantly higher than estimates of overall U.S. professional turnover of 15.7%.
Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has significantly increased the capacity of its U.K. facilities.